Skip to main content
. Author manuscript; available in PMC: 2022 May 16.
Published in final edited form as: Cancer Drug Resist. 2022 Jan 4;5:80–89. doi: 10.20517/cdr.2021.112

Figure 2.

Figure 2.

(A) Initial volume responses of 34 RMS models to cycle 1 of vincristine + actinomycin D + cyclophosphamide (VAC) using the SMT experimental design (ongoing expt.). (B) Kaplan-Meier plot for EFS of the same models. RMS: Rhabdomyosarcoma; VAC: vincristine/actinomycin-D/cyclophosphamide; EFS: event-free survival; SMT: single mouse testing.